Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | MLKL | Q8NB16 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | ALPI | P09923 | 1/20 | 0.45 |
| ▸ | ALPG | P10696 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24998835 | 0.88 | SCN10A (0.56) | SCN10AKDM4ELMNAHSD17B10CYP1A2 | |
| SCHEMBL2706618 | 0.86 | KDM4E (0.57) | SCN10AKDM4ELMNAHSD17B10CYP1A2 | |
| SCHEMBL889358 | 0.85 | HSD17B10 (0.59) | SCN10AKDM4ELMNAHSD17B10CYP1A2 | |
| SCHEMBL23815820 | 0.85 | SCN10A (0.71) | SCN10AKDM4ELMNAHSD17B10CYP1A2 | |
| SCHEMBL25698163 | 0.82 | SCN10A (0.56) | SCN10AKDM4ELMNAHSD17B10CYP1A2 | |
| SCHEMBL23815615 | 0.82 | SCN10A (0.58) | SCN10AKDM4ELMNAHSD17B10CYP1A2 | |
| SCHEMBL890080 | 0.81 | CYP1A2 (0.75) | SCN10AKDM4ELMNAHSD17B10CYP1A2 | |
| SCHEMBL5987543 | 0.81 | ALDH1A1 (0.58) | SCN10AKDM4EHSD17B10CYP1A2ALDH1A1 | |
| SCHEMBL17821440 | 0.80 | SCN10A (0.55) | SCN10AKDM4ELMNAHSD17B10CYP1A2 | |
| SCHEMBL21335366 | 0.80 | KDM4E (0.57) | SCN10AKDM4ELMNAHSD17B10CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230285569-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF FRAGILE X | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230242534-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242534-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| US-20100168138-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-07-01 | — | — | US | disclosed |
| US-7713701-B2 | DNA-binding polymers | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090264426-A1 | Bicyclic aromatic substituted pyridone derivative | MSD K.K. (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090155202-A1 | DNA-BINDING POLYMERS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2009-06-18 | — | — | US | disclosed |
| US-7452730-B2 | DNA-binding polymers | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-11-18 | — | — | US | disclosed |
| US-20080269138-A1 | Polyamides with tail structures | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168138-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | SCN10A 4583/4885KDM4E 2318/4885LMNA 3118/4885 |
| US-20100267634-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | SCN10A 4583/4885KDM4E 2318/4885LMNA 3118/4885 |
| US-20080269138-A1 | Polyamides with tail structures | HNRNPH3, PCNA, DNAH12 | SCN10A 3872/4885KDM4E 1338/4885LMNA 533/4885 |
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | SCN10A 2866/4885KDM4E 4095/4885LMNA 1249/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | SCN10A 4134/4885KDM4E 1193/4885LMNA 2800/4885 |
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | SCN10A 4583/4885KDM4E 2318/4885LMNA 3118/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | SCN10A 2390/4885KDM4E 2603/4885LMNA 2020/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | SCN10A 2509/4885KDM4E 4219/4885LMNA 2015/4885 |
| US-20230285569-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF FRAGILE X | CYFIP2, TPX2, CYFIP1 | SCN10A 1176/4885KDM4E 1660/4885LMNA 1622/4885 |
| US-20230242534-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | CDK2, CDK5, CDK9 | SCN10A 3783/4885KDM4E 1465/4885LMNA 1562/4885 |
| US-20090155202-A1 | DNA-BINDING POLYMERS | PCNA, DDB1, TOP2A | SCN10A 4417/4885KDM4E 2859/4885LMNA 2336/4885 |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | SCN10A 4642/4885KDM4E 2496/4885LMNA 1353/4885 |
| US-20090264426-A1 | Bicyclic aromatic substituted pyridone derivative | PYCR1, CHRM1, MTR | SCN10A 3601/4885KDM4E 1819/4885LMNA 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.